In a market where clinical timelines and capital discipline increasingly shape sentiment, Bolt Biotherapeutics Inc. (BOLT) has emerged as a name drawing renewed attention.
The stock posted a modest gain of 3.33% in after-hours trading, rising to $6.05 following a 2.36% uptick during the regular session. While the move may appear incremental, it comes amid a series of strategic and clinical updates that signal a recalibration of the company's near-term trajectory.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.